Publications and Investor Resources

UTILITY therapeutics is a biotechnology company focused on the US development and commercialization of 2 European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections.

Our approach is to identify exceptional candidates who meet urgent needs and draw on our expertise to expedite approval and make new options available to healthcare professionals and patients as quickly as possible.

News and Updates

Nothing found.

Investor Resources

Investor Relations Contact

UTILITY therapeutics at info@utilitytherapeutics.com